Back to search
Type 1 Facioscapulohumeral Muscular Dystrophy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Type 1 Facioscapulohumeral Muscular Dystrophy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Type 1 Facioscapulohumeral Muscular Dystrophy trials you may qualify forThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-DUX4 in participants with facioscapulo…
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumer…
Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscl…
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or me…
The goal of this study is to investigate the effects of personalized exercise treatment on dynamic balance and physical function in comparison with regular foll…
The data to be collected is intended to help healthcare providers make important medical and financial decisions concerning FSHD1, through an enhanced understan…
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Effica…
The facial-glenohumeral muscular dystrophy type 1 (DMFSH1) is characterized by a selective and asymmetrical involvement of the facial muscles, the shoulder gird…
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common adult muscular dystrophy with an estimated prevalence range of 2-7 per 100,000. The dise…